- Home
- MPB vs CRGX Comparison
MPB vs CRGX Comparison
Compare MPB & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- CRGX
- Stock Information
- Founded
- MPB 1868
- CRGX 2021
- Country
- MPB United States
- CRGX United States
- Employees
- MPB N/A
- CRGX N/A
- Industry
- MPB Major Banks
- CRGX
- Sector
- MPB Finance
- CRGX
- Exchange
- MPB Nasdaq
- CRGX Nasdaq
- Market Cap
- MPB 525.0M
- CRGX 628.6M
- IPO Year
- MPB N/A
- CRGX 2023
- Fundamental
- Price
- MPB $29.19
- CRGX $3.70
- Analyst Decision
- MPB Buy
- CRGX Hold
- Analyst Count
- MPB 2
- CRGX 7
- Target Price
- MPB $36.00
- CRGX $4.67
- AVG Volume (30 Days)
- MPB 71.0K
- CRGX 1.9M
- Earning Date
- MPB 01-22-2025
- CRGX 03-20-2025
- Dividend Yield
- MPB 2.74%
- CRGX N/A
- EPS Growth
- MPB 14.41
- CRGX N/A
- EPS
- MPB 2.91
- CRGX N/A
- Revenue
- MPB $173,416,000.00
- CRGX N/A
- Revenue This Year
- MPB N/A
- CRGX N/A
- Revenue Next Year
- MPB $19.26
- CRGX N/A
- P/E Ratio
- MPB $10.05
- CRGX N/A
- Revenue Growth
- MPB 4.93
- CRGX N/A
- 52 Week Low
- MPB $19.20
- CRGX $3.00
- 52 Week High
- MPB $33.87
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- MPB 46.67
- CRGX 20.88
- Support Level
- MPB $30.02
- CRGX $3.00
- Resistance Level
- MPB $31.36
- CRGX $3.88
- Average True Range (ATR)
- MPB 0.75
- CRGX 0.92
- MACD
- MPB 0.16
- CRGX -1.00
- Stochastic Oscillator
- MPB 45.23
- CRGX 5.99
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.